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Clinical short communication
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Background: Apathy remains a disabling symptom in Parkinson’s disease (PD) with limited therapeutic success.
Processing of emotions and smell share neuroanatomical and evolutionary pathways.
Objectives: To explore the association of apathy with smell dysfunction (SD) in early PD.
Methods: We analyzed patients with de-novo PD, with follow-up of at least 5 years from the Parkinson’s Pro
gression Markers Initiative. SD and apathy were defined using University of Pennsylvania Smell Identification
Test and MDS-UPDRS part 1A. Odds ratios were calculated between apathy and olfaction groups. Kaplan-Meier
survival analysis was grouped by presence/ absence of smell dysfunction. The Log Rank test was used to compare
time to apathy.
Results: We found no association between presence of apathy in patients with and without SD (OR 1.01
[0.49–2.08]). There was no significant difference between PD patients with and without SD in time to apathy (p
= 0.72).
Conclusions: SD does not portend greater risk of apathy in PD.

1. Introduction
The sense of smell, one of the most primitive human sensory mo
dalities, is closely related to emotions [1]. Processing of emotions and
smell share neuroanatomical commonalities, including the amygdala,
insula, anterior cingulate cortex, and orbitofrontal cortex [2]. Apathy
and smell dysfunction (SD) are both prevalent in people with Parkin
son’s disease (PD) [3]. Apathy is characterized by a lack of motivation
and goal-oriented behavior, in the setting of reduced emotional
expression. It is seen in 17–60% of people with PD and may be highly
disabling [4]. To date, there are no reliable, evidence-based treatment
modalities for apathy in PD [5]. Through this effort, we seek to assess the
effect of SD on apathy risk in PD. Such an association would posit the
possibility of a novel therapeutic approach to address apathy in PD.
2. Methods
We analyzed data on patients with early de-novo idiopathic PD,
enrolled within 2 years of motor symptom onset in the Parkinson’s
Progression Markers Initiative (PPMI) study. The PPMI is a prospective
multicohort study that identifies clinical, imaging and biologic markers

of PD progression for use in clinical trials of disease-modifying therapies.
Details on the PPMI methods and objectives have been published else
where [6]. We defined SD as a University of Pennsylvania Smell Iden
tification Test (UPSIT) score performed at the baseline visit at or below
the 10th percentile by age and gender. Apathy was identified using the
Movement Disorders Society United Parkinson’s Disease Rating Scale
(MDS-UPDRS) part 1A item 1.5 with a score of 1 or more. Cognitive
impairment was determined on the basis of criteria developed by the
Movement Disorders Society as applied by the PPMI investigators and
detailed in the original study [6]. To be included in the analysis, the PD
patients needed to have a follow-up period of 5 years, not have apathy at
the initial visit and have more than one visit. Cognitive assessment was
done using the Montreal Cognitive Assessment (MoCA).
Odds ratios were calculated between apathy and olfaction groups
(presence or absence of smell dysfunction). Kaplan-Meier survival
analysis was grouped by presence or absence of smell dysfunction, and
the Log Rank test was used to compare length of time until the onset of
apathy. Cox regression analysis was conducted with apathy as the
dependent variable, and age at the time of the first visit, Hoehn-Yahr
(HY) stage at the time of the first visit, MDS-UPDRS part III score at
the time of the first visit, presence of SD at the time of the first visit,
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depression at the time of the first visit, and the State-Trait Anxiety In
ventory (STAI) at the time of the first visit as the independent variables
and hazard ratios (HR) were calculated and confidence intervals at 95%
are presented in brackets. Models were executed with and without
depression and STAI to account for potential collinearity. All analyses
were performed using SAS 9.4 (SAS Institute Inc., Cary, NC, USA).

anxiety [9]. In clinical practice [4] and in investigations, emotional
dysfunction may be misconstrued as apathy, thereby confounding con
clusions and misguiding proposed interventions [5].
The lack of association between apathy and smell dysfunction in PD
in our analyses persisted even after controlling for other serotonergic
manifestations namely depression and anxiety, thereby strengthening
our conclusion. A factor that we could not account for was the use of
serotonergic drugs that patients could have been using for the treatment
of depression, as the PPMI database does not have information regarding
their use [6]. We expect that controlling for depression and anxiety
would, at least partially, offset the contribution of these missing data on
serotonergic drug use. As previously mentioned, confounding effects of
cognitive or emotional factors may not be addressed. Indeed, the prev
alence of apathy is reduced by half to 20% once these factors are
considered. Another factor to consider is the discrepancy between
apathy reported by the patient and their care partners, with the latter
perhaps reporting a higher severity due to the burden experienced [5].
Our analysis used available MDS-UPDRS data for the determination
of apathy. Such an approach has been previously used for this purpose [
[11,12]]. This relationship between olfaction and apathy has been
previously investigated in PD patients with differing results, albeit in a
different study population and using different tools. Hong and col
leagues utilized the Cross Cultural Smell Identification Test (CCSIT) for
olfaction and the neuropsychiatric inventory (NPI) to identify apathy.
[13] Cramer performed a cross sectional study using the Brief Smell
Identification Test (B-SIT) and the Apathy Evaluation Scale (AES). [3]
The use of different apathy scales such as the AES [3] and the Neuro
psychiatric Inventory (NPI) [13], might be at least partially, be
responsible for the different conclusions than ours. In addition, the pa
tient population in both studies was older, had a longer duration of
disease, with worse motor symptoms. Our analysis was able to comment
on the impact of impaired olfaction on the onset of apathy based on
longitudinal data on patients with early PD.
Previous studies with a relatively small sample size showed mild
benefit with istradefylline, rivastigmine, and piribedil. Unlike benefits
seen with motor symptoms, deep brain stimulation (DBS) may instead
induce apathy after a few months in up to 54% of patients at 1 year after
implantation [5]. This phenomenon has been postulated to be related to
levodopa withdrawal and mesolimbic pathway denervation. Several
non-pharmacologic interventions have been studied in the past,
including exercise, behavioral therapy and cognitive stimulation, of
which only exercise has demonstrated a mild benefit. Additionally, it is
possible that some of these interventions target comorbidities that can
simulate apathy, such as cognitive impairment or depression. Smell
training has been proposed as an effective approach, most recently for
patients suffering from hyposmia during COVID. This approach has a
basis in evidence [14]. While our results based on group data argue
against this perspective as a potential therapeutic approach for apathy, it
is possible that such an endeavor requires specific smells evoking an
emotional response for that individual [1].
Our analysis is not without limitations. While the MDS-UPDRS scale
for determination of apathy has been used before, it relies on a single
item with no objective grading. The Lille Apathy Rating Scale (LARS)
might be a better way to establish the presence of apathy [5]. As
mentioned above, this heterogeneity in tools to assess apathy likely
contributes to the variability in conclusion. While the protocol ac
knowledges that patients will begin to have cognitive dysfunction and
enforce a research proxy for every patient, there is no recording in the
dataset as to who provided the information in each visit leading to
heterogeneity in the source of information. Even though we controlled
for potential confounding variables, the lack of a standardized interview
and assessment for the evaluation of apathy is a potential limitation.
Apathy is a common and highly disabling feature in PD, with rela
tively few and mildly-effective pharmaco-therapeutic strategies and no
proven non-pharmacological approaches. Appropriate recognition,
management of confounders and larger clinical trials are needed, along

3. Results
A total of 486 PD patients were included in our analysis. There was
no significant difference in UPSIT scores between patients with and
without apathy at the beginning (23.4 and 23.5 respectively, p = 0.89)
or at the end of the follow up period (22.9 and 23.6 respectively, p =
0.5). We found no association between the presence of apathy when
comparing patients with and without SD (OR 1.01 [0.49–2.08])
(Table 1).
There was no significant difference between PD patients with and
without SD in time to onset of apathy when comparing the survival
curves presented in Fig. 1 (p = 0.72). This multivariate analysis also
included age (HR 1.02, [1–1.04]), HY stage at the time of the first visit
(HR 0.99[0.64–1.53]), MDS-UPDRS part III score at the time of the first
visit (HR 1 [0.98–1.02], presence of SD at the time of the first visit (HR
0.79 [0.43–1.45]), depression at the time of the first visit (HR 1.48
[0.83–2.63]), and STAI score at the time of the first visit [1–1.02]). CIndex was 0.838 [CI95 0.69–0.95]. Removal of depression and STAI
from the model did not lead to a significant change (p = 0.180) (age HR
= 1.02 [1.00–1.04], HY stage HR = 1.05 [0.68–1.62], MDS-UPDRS part
III HR 1.01 [0.98,1.03], SD HR 0.81 [0.44,1.48]. C-index = 0.892
[0.76–0.98]). For both these models, C-index indicated a good measure
of fit.
4. Discussion
Specific smells may elicit distinct emotions. The sense of smell in
humans has been linked to emotions and associated behavior through an
evolutionary mechanism [7]. The brain circuitry associated with apathy
shares a neuroanatomical pathway with olfaction [2]. Clinically, a
relationship between apathy and smell has been shown to exist in pa
tients with probable Alzheimer’s disease. A mild association has previ
ously been reported in PD patients. However, these were further along in
their disease course, and with data confounded by dopaminergic med
ications [3,8]. Our analyses, conducted on a large sample size of de-novo
PD patients within 5 years of symptom onset, indicates no clinical as
sociation between smell dysfunction and apathy.
In addition to the dopaminergic pathway, progressive degeneration
of the serotonergic meso-cortico-limbic pathway is seen in PD patients
with apathy, depression and anxiety. A correlation between hypomimia
has been established with apathy, without increased prevalence of
depression, anxiety, or cognitive impairment. It serves as an example
with such shared pathophysiological mechanism, related to altered in
teractions between the basal ganglia, prefrontal cortex and the limbic
system [10]. Such a clinical presentation, common among PD patients,
has been described as a “neuropsychiatric lesional profile” in reference
to common underlying serotonergic pathways in apathy, depression and
Table 1
Demographic information stratified per the presence or absence of apathy.
Age at first visit
Female sex
Montreal cognitive assessment
MDS-UPDRS part III at first visit (mean)
Depression
STAI score (mean)
Smell dysfunction
Normal olfaction

Apathy

No apathy

61.15
32.86%
27.05
21.34
83.69%
67.4
60 (14.39%)
10 (14.49%)

61.64
35.34%
27.61
19.81
86.96%
60.84
357 (85.61%)
59 (85.51%)

2
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Fig. 1. Kaplan-Meier curves grouped by olfactory dysfunction compared to normal olfaction in Parkinson’s disease. Events were defined as a new onset of apathy not
present in the previous visit.

with exploration of novel therapeutics for adequate care of our patients.
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